Research and Markets: Genentech's Ethical Sales Forecast to Grow from $3,749m in 2004 to $9,192m in 2010

Business Wire, June 17, 2005

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c19358) has announced the addition of PharmaVitae 2005: Genentech Global Analysis to their offering

This analysis examines the current position and future outlook for Genentech in the biotechnology sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

This report allows you to benchmark Genentech's performance against key rivals in the biotechnology sector. It will give you an understanding as to why Genentech's ethical sales are forecast to grow from $3,749m in 2004 to $9,192m in 2010. This report also provides insight into why Genentech should drive long-term growth of their oncology franchise by developing fully human monoclonal antibody products.

Key topics covered in the report include:

- Key findings

- Current positioning: competitive outlook 2004

- Future performance: growth drivers and resistors 2005-10

- Evolution in therapeutic focus: 2004 - 10

- Key issues facing Genentech: 2004 - 10

- Strategic outlook

For more information visit http://www.researchandmarkets.com/reports/c19358